西藏药业股价报46.04元，较前一交易日下跌1.62%。盘中最高触及46.70元，最低下探至45.69元，成交量为98714手，成交金额达4.54亿元。
西藏药业属于生物制品行业，公司主要从事中成药、藏成药及化学药品的研发、生产和销售。2025年半年报显示，公司投资3亿元参股江苏晨泰医药，持股比例为13.04%。晨泰医药研发的佐利替尼是全球首款针对伴中枢神经系统转移的晚期非小细胞肺癌开展注册临床试验并取得显著成果的药物。
8月22日主力资金净流出3891.59万元，近五个交易日累计净流出9780.61万元。
风险提示：股市有风险，投资需谨慎。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.